# 1 Unravelling Chlamydia trachomatis Diversity in

# 2 Amhara, Ethiopia: MLVA-ompA Sequencing as a

# 3 Molecular Typing Tool for Trachoma



- Anna Harte<br>Sata<sup>2</sup>, Gizach<br>Holland<sup>1</sup>.<br><sup>1</sup>The London<br><sup>2</sup>The Carter , Ensan Gnasemian<br>1ew Yismaw<sup>3</sup>, Taye 2<br>1<br>School of Hygiene<br>Center, Addis Ababa , Harry Pickering<br>Zeru<sup>3</sup>, Zerihun Tac<br>and Tropical Med<br>1, Ethiopia , Joanna Houghton<br>desse<sup>2</sup>, E. Kelly Calla<br>icine, London, UK 4 Anna Harte<sup>1</sup>, Ehsan Ghasemian<sup>1</sup>, Harry Pickering<sup>1</sup>, Joanna Houghton<sup>1</sup>, Ambahun Chernet<sup>2</sup>, Eshetu<br>Sata<sup>2</sup>, Gizachew Yismaw<sup>3</sup>, Taye Zeru<sup>3</sup>, Zerihun Tadesse<sup>2</sup>, E. Kelly Callahan<sup>4</sup>, Scott D. Nash<sup>4</sup>, Martin<br>Holland<sup></sup> Sata<sup>2</sup>, Gizachew Yismaw<sup>3</sup>, Taye Zeru<sup>3</sup>, Zerihun Tadesse<sup>2</sup>, E. Kelly Callahan<sup>4</sup>, Scott D. Nash<sup>4</sup>, Martin<br>6 Holland<sup>1</sup>.<br>7<br><sup>1</sup>The London School of Hygiene and Tropical Medicine, London, UK<br><sup>2</sup>The Carter Center, Addis Ab
- sata<br>Holla<br><sup>1</sup>The<br><sup>2</sup>The
- 7
- , Gizachew Yismaw<br>nd<sup>1</sup>.<br>London School of H<sub>)</sub><br>Carter Center, Addis<br>Amhara Regional He , Taye Zeru<br>ygiene and T<br>3 Ababa, Eth<br>ealth Bureau , Zerihun Tadesse<br>Propical Medicine,<br>2010<br>1, Bahir Dar, Ethiop , E. Kelly Callahan<br>London, UK<br><sup>pia</sup> 6 Holland<sup>1</sup>.<br>7<br>8 <sup>1</sup>The Lond<br>9 <sup>2</sup>The Carte<br>0 <sup>3</sup>The Amh<br>1 <sup>4</sup>The Carte  $8$  <sup>1</sup>The London School of Hygiene and Tropical Medicine, London, UK
- 9 <sup>2</sup>The Carter Center, Addis Ababa, Ethiopia
- The Carter Center, Addis Ababa, Ethiopia<br>The Amhara Regional Health Bureau, Bahir Dar, Ethiopia<br>The Carter Center, Atlanta, GA, USA<br>**Abstract**  $10$  <sup>3</sup>The Amhara Regional Health Bureau, Bahir Dar, Ethiopia
- 11 <sup>4</sup>The Carter Center, Atlanta, GA, USA
- 12

# 13 Abstract

The Amhara Regional Health Bureau, Bah<br>The Carter Center, Atlanta, GA, USA<br>**Abstract**<br>Trachoma is the leading infectious cau: The Carter Center, Atlanta, GA, USA<br>The Carter Center, Atlanta, GA, USA<br>Trachoma is the leading infectious cause of blindness<br>o around 40 low- and middle-income countries. It is The Cartesian Chartesian<br>The Cartesian States<br>The Cartesians, Atlanta, Gardierina<br>Contagious, intracellular, bacter 14 Trachoma is the leading infectious cause of blindness worldwide and is now largely confined<br>to around 40 low- and middle-income countries. It is caused by *Chlamydia trachomatis (*Ct), 15 a contagious intracellular bacterium. The World Health Organization recommends mass 16 drug administration (MDA) with azithromycin for treatment and control of ocular Ct 17 infections. To understand the molecular epidemiology of trachoma, especially in the context 18 of MDA and transmission dynamics, the identification of Ct genotypes is a necessity. While 19 of MDA and transmission density.<br>Many studies have used the Ct major outer membrane protein (o*mp*A) for genotyping, it has 20 many studies have used the Ct major outer membrane protein (o*mpA)* for genotyping, it has<br>limitations. 21



cost-effectiveness and efficiency relative to whole genome sequencing, providing valuable 35 information for trachoma control programs on local epidemiology. The findings suggest the 36 potential of MLVA-ompA as a reliable tool for typing ocular Ct and understanding 37 transmission dynamics, aiding in the development of targeted interventions for trachoma 38  $t$  transmission dynamics, and the development of targeted interventions for the development of the develop 39

40

# 41 Author Summary

42 Trachoma is the leading infectious cause of blindness worldwide and is largely confined to<br>low- and middle-income countries. It is caused by *Chlamydia trachomatis* (Ct), a contagious 43 intracellular bacterium. The World Health Organization recommends mass drug 44 administration (MDA) with the antibiotic azithromycin for treatment of ocular Ct infections. 45 administration (MDA) with the antibiotic azithromycin for treatment of ocular Ct infections.

46 In most regions MDA is successfully reducing trachoma prevalence to the point where it is<br>no longer a public health issue, however in some places trachoma persists despite multiple 47 rounds of treatment. To investigate why trachoma persists, especially in the context of MDA 48 and transmission dynamics, the identification of Ct genotypes is necessary. Our study 49 applies a novel Ct typing system, which augments the standard method by adding three loci 50 with high mutation rates. Results show that the novel typing system was able to 51 discriminate between variants with greater resolution than the standard method, and was 52 both cost-effective and more efficient relative to the gold-standard of whole genome 53 sequencing. The findings suggest that this novel method is a reliable tool for typing ocular 54 Ct, which can aid in the development of targeted interventions for trachoma control. 55 Ct, which can aid in the development of targeted interventions for trachoma control.

56

## 57 Introduction

58

59 Trachoma is the leading infectious cause of blindness worldwide (1) and is found primarily in<br>about 40 low- and middle-income countries (LMIC). It is caused by *Chlamydia trachomatis* 60  $(Ct)$ , a contagious intracellular bacterium with 4 serotypes (A, B, Ba and C) that are typically 61 responsible for ocular infection in trachoma endemic countries. The World Health 62 Organization (WHO) recommends the use of the Surgery, Antibiotics, Facial Cleanliness, and 63 Environmental improvement (SAFE) strategy, including mass drug administration (MDA) of 64 the antibiotic azithromycin for controlling trachoma (1). Multiple rounds of MDA are usually 65 required which is determined by the prevalence of clinical signs within the district. 66 Reinfection can occur within months of treatment (2-4), and the clinical signs of disease 67 often persist in the population while ocular Ct infection is low or absent (5,6). The 68 surveillance of Ct strains is of interest for monitoring transmission dynamics, as well as 69 surveillance of  $C$  surveillance of  $C$  interest for monitoring transmission dynamics, as well as

70 identifying the potential dominance of individual strains, which may indicate selection by<br>antibiotics or increased virulence, persistent infection and/or re-infection (7).

71 antibiotics or increased virulence, persistent infection and  $\rho$  re-infection (7).

72

73 Molecular epidemiological studies of Ct infection within communities often focus on the<br>outer membrane protein A (ompA) gene, as this codes for the polymorphic major outer 74 membrane protein (MOMP), a key chlamydial antigen targeted by the host immune system 75 and one therefore theoretically subject to immune selection  $(8-11)$ . However, previous 76 work on genital (D-K) and Lymphogranuloma venereum (LGV) serovars has demonstrated 77 that *ompA* genotyping alone has insufficient discriminatory power  $(12-15)$  for the reliable 78 identification of truly different variants within a population (16). Since recombination within 79  $ompA$  has been demonstrated, this may also obscure true phylogenetic relationships (17). 80 ompA has been demonstrated, this may also obscure true phylogenetic relationships (17).<br>81 OWhole-Genome Sequencing (WGS) should offer the highest resolution for variant 81 identification; however, it remains prohibitive in terms of cost, equipment, high technical 82 expertise and large sample load required, placing this beyond the access and feasibility for 83 trachoma control programmes operating in LMIC. To address this, several polymerase chain 84 reaction (PCR)-amplicon sequence-based typing methods have been developed, where two 85 or more loci are amplified and then subjected to chain termination sequencing (Sanger 86 sequencing) for each individual sample. 87

88

sequencing) for each individual sample.

89 These typing systems have been used to investigate Ct strain diversity, each with varying<br>levels of discriminatory power (7). Multi-locus sequence typing (MLST) and multiple loci 90 variable number of tandem repeat analysis (MLVA) are two types of PCR sequencing that 91 use sequence types (ST) to define different variants. Classic MLST is focused on sequence 92 variation in loci that are not considered to be under selection pressure and are stable 93 variation in loci that are not considered to be under selection pressure and are stable

94 housekeeping genes (18,19) and is best suited to long-term and global epidemiology. Other<br>MLST studies have used highly variable loci instead, to improve variant resolution on a 95 smaller epidemiological scale  $(20-22)$ . MLVA provides a further alternative and uses 96 variable number tandem repeats (VNTR), which have a higher rate of mutations (23) and 97 can therefore provide a useful identifier of novel strains for small scale, local 98 epidemiological studies (22). MLST methods have been applied to ocular serovars and in 99 trachoma epidemiology (20,24,25), however MLVA has not yet been used to investigate the 100 molecular epidemiology of trachoma. 101 molecular epidemiology of trachoma.

102

103 In this study conjunctival DNA collected from children living in trachoma-endemic areas of<br>Amhara, Ethiopia, which were surveyed between 2011 and 2017, were used to sequence 104 three VNTR loci and ompA as outlined by Pedersen et al., (2008). The aim of this study was 105 to determine the efficacy of MLVA-ompA when applied to ocular samples and test the 106 discriminatory power (DP). We then investigated whether MLVA-ompA variants were 107 associated with clinical signs of trachoma and the impact of MDA on variants in the 108 population. We propose that MLVA-ompA typing could serve as a tool for the surveillance of 109 emerging Ct variants within the context of localized epidemiological studies. Additionally, it 110 can be employed to establish a profile of the evolutionary dynamics of Ct variants over time 111 within populations remaining endemic to trachoma. 112 within populations remaining endemic to trachoma.

- 113
- 114 Methods

115

116 Study population

118 The SAFE strategy was scaled up between 2007 and 2010 to reach all districts in Amhara.<br>Between 2011 and 2015 all districts were then surveyed to measure the impact of 119 approximately 5 years of SAFE interventions on trachoma prevalence  $(26,27)$ . Impact 120 surveys use multi-stage sampling, and trained and certified graders use the WHO-simplified 121 grading system (28) to determine the presence of the trachoma clinical signs trachomatous 122 inflammation-follicular (TF), trachomatous inflammation-intense (TI) and trachomatous 123 scarring (TS) (27). As part of these surveys, conjunctival swabs were collected to estimate 124 population-based prevalence of Ct infection among children aged 1 to 5 years (26). Impact 125 surveys, including conjunctival swabbing, were repeated throughout the region between 126 2014 and 2021 after an additional 3 to 5 years of interventions (29,30). The samples used in 127 this study were a subset of those collected between 2011-1015 from 58 surveyed districts 128 which make up four zones (North Gondar, South Gondar, East Gojam and Waghemra) (29). 129 An additional subset of samples used in this study came from all 11 districts in South Gondar 130 zone, collected between 2014 and 2017 as part of the second round of surveys. Each 131 individual was given a unique ID code which was not known to anyone outside of the 132 individual was given a unique ID code which was not known to any the outside of the<br>research group. 133 research group.

134

#### 135 Ethical approval

136

137 The ethical approvals associated with the collection and processing of these samples have<br>been described previously (27,29,31). Survey methods were reviewed and approved by the 138 Emory University Institutional Review Board (protocol 079-2006) as well as by the Amhara 139 Regional Health Bureau. Due to elevated levels of illiteracy within the community, 140 permission was granted for obtaining verbal consent or assent. Electronic recording of oral 141 permission was granted for obtaining verbal consent or assent. Electronic recording of oral 142 consent or assent was implemented for all individuals, aligning with the principles outlined 143

any juncture without the need for providing an explanation. 144 any juncture without the need for providing an explanation.

145

#### $146$  DNA extraction and sample preparation for sequencing

147

148 The initial testing of samples was performed at the Amhara Public Health Institute in Bahir<br>Dar, Ethiopia. Swabs were randomised and pooled into batches of five samples per pool, 149 and tested for two highly conserved Ct plasmid targets using the Abbott Realtime assay on 150 the Abbott m2000 (Abbott Molecular Inc., Des Plaines, IL, USA) (26). For the subset of 151 districts included in this study, individual samples from positive pools were assayed again to 152 determine individual level infection. Ct load was determined by converting the Abbott 153 m2000 delta cycle to elementary body (EB) count using an EB standard curve, generated 154 using a standard set of EB titrations (29,32). There were 525 Ct positive samples collected 155 from these study districts. 300 samples with the highest Ct load were chosen for further 156 sequencing analysis. DNA was re-extracted from all 300 conjunctival swabs as previously 157 described (31). 99 samples with a sufficiently high Ct load were chosen for WGS, the results 158 of which have already been published, including the bioinformatic extraction of the ompA 159 region (31). For the remaining 201 samples,  $ompA$  was sequenced by Sanger sequencing, 160 however for the three VNTRs of interest, CT1291, CT1299 and CT1335, all 300 samples were 161 sequenced by Sanger sequencing Reference sequences from serovars A (A/2497: Acc. 162 FM872306; A/HAR13: NC 007429), B (B/Jali20/OT: Acc. FM872308; B/Tunis864: 163 ERR12253485), C (C/TW-3, Acc. NC 023060), D (D/UW3/CX, Acc. NC 000117), and L 164 ERR12253485), C (C/TW-3, Acc. NC\_023060), D (D/UW3/CX, Acc. NC\_000117), and L 165 (L3/404/LN: Acc. HE601955; L2/434/Bu: Acc. AM884176) were also sequenced for the three 166

VNTR regions to compare between published WGS sequences.

167

- 168 ompA Sanger sequencing preparation
- 169

170 Prior to sequencing, the extracted eye swab DNA underwent one or two rounds of PCR<br>using a nested PCR, following the procedure outlined in Andreasen et al. 2008, (11). For the 171 first round, 20  $\mu$ L of 5prime MasterMix (QuantaBio), 20  $\mu$ L of molecular grade water 172 (Corning, Manassas, VA20109 USA), 2.5  $\mu$ L each of forward and reverse primers ompA-87 173 and  $ompA-1163$  and 5  $\mu$ L of DNA template were run using the cycling conditions as follows: 174 Initial denaturation of 2 min at 94 °C, then 35 cycles of 94 °C for 15 S and 62 °C for 75 S, and 175 a final elongation step of 72 °C for 10 min. This PCR resulted in a product of 1076 base pairs 176 (bp) in size. Samples were run on a gel, and if no band was present, nested PCR was 177 performed. For the second round of PCR, 10 µL 5Prime HotMasterMix (QuantaBio), 1.25 µL 178 performed. For the second round of PCR, 10 pc second round community (QuantaBio), 1.25 pc<br>ompA-87 and 1.25 µL ompA-1059 primers and 11.5 µL molecular grade water (Corning, 179 ompA-87 and 1.25  $\mu$ L ompA-1059 primers and 11.5  $\mu$ L molecular grade water (Corning,<br>180 Manassas, VA20109 USA) were added to 1  $\mu$ L of a 1 in 200 dilution of the PCR product from 180 Manassas, VA20109 USA) were added to 1  $\mu$ L of a 1 in 200 dilution of the PCR product from<br>the first round. The final product size of the target sequence (ompA-inner) was 972 bp in 181 length. This product was then cleaned using a ratio of  $0.8$  X final volume of AMPure XP 182 magnetic beads (Beckman Coulter) following the manufacturer's instructions, quantified on 183 the Qubit 2.0 Fluorometer (Thermo Fisher) and diluted to a concentration of  $\gamma$ 10 ng/ $\mu$ L. 184 Samples were sent to Source BioScience (Cambridge, UK) with ompA-97 forward primer 185 Samples were sent to Source BioScience (Cambridge, OK) with o*mpA-*97 forward primer<br>and/or *ompA*-1059 for samples sequenced in both directions. 186 and/or ompA-1059 for samples sequenced in both directions.

187

188 VNTR sequencing preparation

189

190 All 300 samples were processed for the VNTRs, with a separate PCR reaction used to amplify<br>each VNTR region. DNA extracted from eight Ct reference samples were also sequenced for 191 comparison with existing genomic data. Samples were run in 25 uL reaction volumes, using 192 5 µL DNA template, 10 µL Accustart (Quantabio, Hilden, Germany), 1.25 µL each forward 193 and reverse primers, and  $7.5 \mu L$  molecular grade water (Corning, Manassas, VA20109 USA). 194 Three different sources of primers were used, due to complications with the proximity of 195 some of the VNTR regions to the start of the sequencing, and the subsequent low-quality 196 bases associated with the first 30-50 bps. For primers sourced from Pedersen et al., (2008) 197 (33) and the new CT1299 forward primer, cycling conditions were 10 min held at 94 °C, then 198 40 cycles of 45 S at 94 °C, 20 S at 59 °C, 20 S at 72 °C, hold at 4 °C. For primers sourced from 199 Labiran et al., (34) the annealing temperature was 56 °C for CT1335 and 60 °C for CT1299. 200 Samples were sent to Source BioScience (Cambridge, UK) with 3.2 pmol of forward primer 201 for each VNTR. CT1299 was sequenced in both the forward and reverse direction for some 202 samples with low quality sequencing due to extended repeat base regions. Primers and 203 amplicon sizes for the three VNTR regions are listed in table 1. Samples that did not produce 204 sufficient sequencing quality to call the sequence type in the first round of sequencing for 205 CT1299 were re-run using a modified CT1299 forward primer to increase the distance 206 between the start of the sequence and the flanking and VNTR region (35). A total of 140 207 samples were tested using the new CT1299 forward primer. 208 samples were tested using the new CT1299 forward primer.

- 209
- 210
- 211
- 212

- 213
- 214
- 
- 215
- 216
- 217
- 218
- 219
- 220
- 221
- 
- Table 1. Forward and reverse primers used to amplify VNTR regions and *ompA* of *Chlamydia trachomatis* in<br>223 Ethiopian conjunctival samples collected between 2011-2017, for Sanger sequencing and the amplicon size<br>224 pro 223
- 224
- 225



#### 227 VNTR calling and MLVA-ompA

228

229 Only VNTR sequences produced by Sanger sequencing were used in further analysis.<br>Sequences were aligned within each respective VNTR using MEGA-X (Version 11.0.13), and 230 the sequence type was recorded by manually counting the number of repeat base pairs as 231 well as the respective flanking regions, following the typing method outlined by Pedersen et 232 al., (33) and Wang et al., (37). Chromatograms were checked to ensure that base-calling was 233 accurate, and sequences were discarded from further analysis if a specific VNTR type could 234 not be assigned. References where WGS sequences were available on National Center for 235 Biotechnology Information (NCBI) from serovars A (A/2497; A/HAR13), B (B/Jali20/OT; 236 B/Tunis864), C (C/TW-3), D (D/UW3/CX), and L (L3/404/LN; L2/434/Bu) were used to 237 compare VNTR-amplicon Sanger sequencing against WGS derived VNTR sequence, alongside 238 comparison of published WGS data from a subset of samples from this study  $(31)$  by 239 comparison of published WGS data from a subset of samples from this study (31) by<br>calculating the kappa statistic. 240 calculating the kappa statistic.

241

#### $242$  ompA serovar calling

243

ompA sequences were extracted from WGS data generated from the 99 samples originally<br>245 analysed in Pickering et al., (31). All WGS sequences were aligned to *omp*A reference 245 sequences A/HAR13, B/Jali20 and C/TW-3 using bowtie2 (38), and samtools (39) was used to 246 extract the matching ompA sequences. The best alignments were selected based on the 247 minimum number of Ns present in the sequence. The 146 Sanger-derived ompA sequences, 248 were separated based on serovar, and aligned within each serovar group to a reference 249 were separated based on serovar, and aligned within each serow group to a reference 250 sequence using MEGA-X; Serovar A (A/HAR13, Acc. DQ064279), serovar B (B/TW-5/OT, Acc.<br>M17342) and serovar Ba (VR-347-Ba, Acc. KP120856).

251  $\mathcal{L}$ 

252

 $253$  Variant types and typeability

254

255 Individual variant types were classified following Pedersen et al., (33), Wang et al., (37), and 256 combination of all three VNTRs within a sample was used to assign MLVA type, with the 257 addition of each ompA type to create the MLVA-ompA variant. Variants are technically the 258 same as strains, however a variant is only referred to as a strain when it shows distinct 259 physical properties, such as the reference strains used for alignments. As we have not 260 investigated any potential physical properties of the variants identified in this study only 261 variant has been used. Typeability was calculated by dividing the number of samples that 262 were successfully sequenced for all three VNTRs and ompA (MLVA-ompA) by the total 263 number of samples available (300). 264 number of samples available (300).

265

- $266$  Diversity and discriminatory power
- 267

268 DP is defined as the ability to distinguish different variants, and is expressed as the<br>probability that two different variants will be placed into different categories. The level of 269 diversity was calculated for each genotyping system with and without associated VNTR-270 flanking regions (individual VNTRs, MLVA, ompA, MLVA- ompA) using Simpson's index of 271 diversity following the recommended modification outlined by Hunter and Gaston (1988) 272 diversity following the recommended modification outlined by Hunter and Gaston (1988)<br>(40). Hutcheson's *t*-test was used to compare the Simpson diversity indices for pre- and 273 (40). Hutcheson's t-test was used to compare the Simpson diversity indices for pre- and 274 post-MDA time points for the South Gondar zone. Data was available from two different<br>time points for South Gondar because surveys were performed after 5 rounds of MDA and 275 8-10 rounds of MDA. Zonal diversity was compared between the two time points using 276 Hutcheson's t-test in the vegan package  $(41)$  in R, to determine if there was a significant 277 change in the level of diversity after extra rounds of MDA. 278 change in the level of diversity after extra rounds of MDA.

279

#### 280 Association analyses

281

282 Association analyses were performed to investigate the relationship between individual<br>level TF and/or TI and the MLVA-*omp*A variants. Due to the high number of low frequency 283 variants, variants were stratified as; high  $(>4)$ , medium  $(2-4)$  and low  $(1)$  frequency, and 284 treated as a categorical variable, with the high frequency group set as the reference. Mixed 285 effects logistic regression (package lme4, R,  $(42)$ ) was performed for each clinical sign, with 286 the three variant categories as the independent variable, adjusting for age, gender and 287 the three variant categories as the independent variable, adjusting for age, gender and<br>district as a random effect. 288

289

290 Association analyses were also performed using village-level TI and TF as the independent<br>variable using generalised linear mixed effects models (Package glmm, R) (43), adjusting for 291 age, gender and district as a random effect. The same model was run using Ct load as the 292 independent variable. District-level Ct, TI and TF prevalence were also used as dependent 293 variables to test the relationship with district diversity, accounting for the number of 294  $v^2$  is the relationship with district district diversity, accounting for the number of the nu 295

296

### 297 Minimum spanning tree and phylogenetic tree analysis

samples per district.

298



309 Results

310

### 311 ompA and VNTR Sequences

312

313 OmpA serovar type derived from WGS was obtained for all 99 Ct WGS. A further 201<br>314 samples that were sequenced for *ompA* using Sanger sequencing generated 146 successful 314 sequences (72.6%). The 55 unsuccessful sequences were due to unreadable chromatograms 315 containing a large proportion of Ns, due to either poor quality DNA or overlapping peaks. 316 These could potentially represent mixed infection with multiple variants however these 317 results cannot be reliably resolved and were excluded. Data was missing in relatively equal 318 proportion over the six years that samples were collected (supplementary table 1). For the 319 three VNTRs generated by Sanger sequencing, CT1291 was successfully sequenced in 320 266/300 samples (88.6%), CT1299 was successful in 252/300 (84%) and CT1335 was 321  $28.6$  samples (88.6%), CT1299 was successful in 252/300 (84%) and CT1335 was successful in  $25.3$ 

322 successful in 255/300 (85%). In total, 194/300 (65%) samples had sequencing results of a<br>high enough quality to call serovar and VNTR sequence types for all three VNTRs (Fig. 1). 323 Sequencing of ompA and the three VNTRs produced variable results, with CT1291 the most 324 successful in terms of typeability  $(88.7%)$  and CT1299 the least  $(84.0%)$  (Table 2, Fig. 2). 325 There were consistent difficulties with sequencing the repeat region of CT1299, with 326 samples exceeding 14Cs demonstrating evidence of polymerase slippage and PCR stutter 327  $(23)$ . Samples with greater than 14Cs in a row were therefore sequenced in both the 328 forward and reverse directions, however 10 CT1299 samples with 15-18 repeat Cs were not 329 able to be confidently identified, and were removed from the dataset. 330



331

Fig. 1. Workflow diagram showing the process of conjunctival swab samples collected between<br>333 2011-2017 from the Amhara region of Ethiopia, and the proportion successfully sequenced for each<br>333 2011-2017 from the Amhara 333 2011- 2017 from the Amhara region of Ethiopia, and the proportion successfully sequenced for each

- 334
- 335



336

Fig. 2. Venn diagram illustrating the overlap in successful Sanger sequencing of each conjunctival<br>338 swab sample collected from Amhara, Ethiopia between 2011-2017 for the three VNTRs and *ompA*.<br>339 Nine samples were not 338 swab sample collected from Amhara, Ethiopia between 2011-2017 for the three VNTRs and *ompA*.<br>Nine samples were not able to be sequenced for any of the VNTRs or *ompA*. VNTR: Variable number<br>tandem repeat. ompA: outer memb 339 Nine samples were not able to be sequenced for any of the VNTRs or *ompA*. VNTR: Variable number<br>tandem repeat. ompA: outer membrane protein A. 340 tandem repeat. ompA: outer membrane protein A. 341

- 342
- 343
- 344
- 345

348

Table 2. Typeability and discriminatory power for each VNTR separately, the VNTRs collectively<br>350 (MLVA), *ompA* and MLVA-*ompA*. Discriminatory power was determined following Hunter and<br>351 Gaston's modified Simpson's di 350 (MLVA), *ompA* and MLVA-*ompA*. Discriminatory power was determined following fruiter and<br>Gaston's modified Simpson's diversity index (Hunter and Gaston, 1987). Typeability is calculated by<br>the number of successful sequenc 351 the number of successful sequencing reactions divided by the total number of samples available. The<br>number of variants for the *ompA* sequencing refers to *ompA* serovars, as determined by homology<br>of each sequence within 352 The number of variants for the *ompA* sequencing refers to *ompA* serovars, as determined by homology<br>of each sequence within the BLAST-n NCBI database.<br>The total database.<br>The total number of scheme within the BLAST-n NCB 353 354





356

357

## 358 VNTR and MLVA-ompA typeability

359

360 The typeability of each VNTR and *omp*A individually were above 80%, however due to a<br>small proportion of dissimilarity between the samples that were not successful for each 361 round of sequencing (Fig. 2), the overall typeability of MLVA-ompA for this study was 64.6%. 362 There was a mix of serovars A, B and Ba across the entire Amhara region from samples 363 collected between 2011-2015 (Fig. 3). A total of 87 variants were found within this 364 collected between 2011-2015 (Fig. 3). A total of 87 variants were found with the 87 variants were found within this were found within the second within this were found within the second within the second within this were f

365 population (DP=0.981). WGS sequences from reference serovar STs deposited in NCBI 366 matched our sample sequencing results for six out of eight reference genomes, with the  $367$  repeat C region in CT1299 resulting in a low quality read for C/TW-3 and a mismatch in 368 CT1299 region for B/Tunis864 (Table 3).

369



370

371 Fig. 3. Map of the Amhara region of Ethiopia showing the location and proportion of Chlamydia 372 trachomatis serovars A, B and Ba at the first sampling time points (2011 -2015) from conjunctival eye 373 swab samples collected after the first five rounds of mass drug administration. The size of the pie 374 chart is proportional to how many samples are represented, with larger pie charts indicating more 375 samples.

- 376
- 377

380

382

383

384

385



386

CT1299 and CT1291 had the highest number of STs with 12 and 8 respectively, with CT1335 387 having 6 STs. Three new STs were recorded for CT1291, two new STs for CT1299 and four 388 new STs recorded in CT1335 (table 4). The frequency of the STs for each VNTR are listed in 389 Table 4a-c. Frequencies for both MLVA and MLVA-ompA show a relatively high proportion of 390 Table 4a-c. Frequencies for both MLVA and MLVA-*omp*A show a relatively high proportion of<br>variant types are singletons since almost half of the MLVA-*omp*A variant types have a 391 variant types are singletons since almost half of the MLVA-ompA variant types have a<br>frequency of one. 392

393

frequency of one.

394

396

397

398

399 **A** 



400

401 **B** 



#### 402

# 403 **C**



404

# 405 Minimum spanning trees

406

407 The MLVA-*omp*A MST (Fig. 4) showed limited defined clustering when separated by year of<br>collection. There was a small cluster from 2013, however the most common variants, 408 represented by larger circles, were present in multiple years. There were also some defined 409 clusters by ompA serovar (supplementary Fig. 1), however the MSTs categorised by rounds 410 of MDA (supplementary Fig. 2) and zone (supplementary Fig. 3) showed limited clusters of 411 variants. There was a small (n= 10) defined cluster of variants collected in East Gojam in 412 2013 that were all ompA serovar B/Ba. 413 2013 that were all ompA serovar B/Ba.





416 Fig. 4. A minimum spanning tree showing the sequence-types identified in the Amhara 417 region of Ethiopia between 2011-2017. Each MLVA-ompA sequence-type (n= 87) is coloured <sup>418</sup>by year of collection. Each circle represents a different sequence-type, with the size of circle 419 being directly proportional to the number of individuals who had that variant. Trees were 420 generated using Phyloviz 2.0.

421

## 422 Phylogenetic trees

423

424 A total of 45 samples provided complete VNTR sequences along with their flanking regions 425 through WGS, which were subsequently utilized to construct a maximum likelihood  $426$  phylogenetic tree (Fig. 5). The remaining 44 samples that were unable to provide a complete 427 VNTR sequence were missing loci due to insufficient sequencing quality in either WGS or





438

Fig. 5. Maximum likelihood phylogenetic reconstruction of multiple loci variable number of<br>440 tandem repeat analysis and flanking region loci bioinformatically extracted from Whole-440 Genome Sequencing (WGS). The phylogenetic analysis encompasses three variable number 441 tandem repeat regions and associated flanking regions resulted from WGS of 45 Chlamydia 442 trachomatis (Ct) positive samples collected in Ethiopia and seven Ct reference strains. 443 trachomatis (Ct) positive samples collected in Ethiopia and seven Ct reference strains.<br>444 Sequences were aligned using MAFFT, and a phylogenetic tree was reconstructed employing 444 PHYML (100 bootstraps). All reference strains are highlighted in blue. 445 PHYML (100 bootstraps). All reference strains are highlighted in blue.

 $0.2$ 



**448 Fig. 6.** Maximum likelihood phylogenetic reconstruction of multiple loci variable number of<br>449 tandem repeat analysis and flanking regions loci-amplicons by Sanger sequencing. The 449 phylogenetic analysis encompasses three variable number tandem repeat regions and 450 associated flanking regions derived from Sanger sequencing of 45 Chlamydia trachomatis 451 (Ct) positive samples collected in Ethiopia and seven Ct reference strains. Sequences were 452 aligned using MAFFT, and a phylogenetic tree was reconstructed employing PHYML (100 453 bootstraps). All reference strains are highlighted in blue. 454 bootstraps). All reference strains are highlighted in blue.

# 456 WGS derived and PCR amplicon VNTR sequence comparisons

457



478

479 Association analyses

same sample (supplementary table 2).

![](_page_26_Picture_86.jpeg)

![](_page_26_Figure_2.jpeg)

488

Fig. 7. Frequency plots for each *Chlamydia trachomatis* variant found in the South Gondar zone,<br>490 Ethiopia, 2011- 2017. The data has been split into two time points- the first, after five rounds of<br>491 MDA (n=43, total 490 MDA (n=43, total number of variants= 30), and the second after an additional three to five rounds of<br>MDA (n=43, total number of variants= 30), and the second after an additional three to five rounds of 491

MDA (n=43, total number of variants= 30), and the second after an additional three to five rounds of

- 492 MDA (n=44, total number of variants= 23). Bars are coloured by each respective serovar. MDA= mass
- $493$  drug administration with azithromycin.

#### 494

![](_page_27_Figure_4.jpeg)

495

496 Fig. 8: Map of the South Gondar zone samples only (Amhara, Ethiopia), showing the range of <sup>497</sup>Chlamydia trachomatis serovars identified from conjunctival swabs collected between 2011-2014 498 after five rounds of MDA (A) and eight to ten rounds of MDA (B) collected between 2015-2017. The 499 size of the pie chart is proportional to how many samples are represented, with larger pie charts 500 indicating more samples.

- 501
- 502

503

- 504
- 505
- 506

- 
- 509
- 510
- 511
- 512

![](_page_28_Picture_127.jpeg)

513

#### 515 Discussion

516

517 Understanding Ct transmission dynamics is an important part of trachoma control, as the<br>identification of Ct genotypes can provide information on the infection source, the presence 518 of repeat or persistent infections, and the impact of antibiotic treatment (48). Different 519 ocular genotypes of Ct may also elicit varying degrees of infection intensity and disease 520 severity (49). The majority of epidemiological studies have primarily focused on ompA, 521 however, this has been shown to be limited in terms of discriminatory power (7). The results 522 from this study have demonstrated that the use of MLVA-ompA can provide a sufficient 523 from this study have demonstrated that the use of MLVA-*omp*A can provide a sufficient<br>524 Fesolution for molecular epidemiology studies in trachoma since it exceeds the 524 recommended guideline value of DP= 0.95 (Van Belkum et al., 2007). MLVA-ompA detected 525 a reduction in Ct diversity with additional rounds of MDA which may mean that while the 526 prevalence of infection remain high in this part of Amhara, the reduction in pathogen 527 population diversity serves as an indicator of treatment impact, possibly indicating the start 528 of a decline in overall infection prevalence. 529

530

531 Application of MLVA by Pedersen et al. (2008) (33) found DP = 0.94, which is consistent with<br>other MLVA-*omp*A studies on genital serovars (50,51). For LGV serovars, analyses testing the 532 other MLVA-*omp*A studies on genital serovars (50,51). For LGV serovars, analyses testing the<br>533 stability of VNTRs suggested MLVA to be a suitable typing method (34), however further 533 testing by the same group on a larger set of LGV clinical samples suggested that MLVA-534  $ompA$  could not reach the recommended 0.95 cut-off (15). Other typing systems such as a 535 ompA could not reach the recommended 0.95 cut-off (15). Other typing systems such as a<br>536 combination of MLST and MLVA (22) and alternate MLVA targets (52) have been shown to 536 have a DP of between 0.6-0.99. The typing system with the highest DP of 0.99, MLST+MLVA, 537 requires 8 individual loci to be sequenced, double the number of this study, for a relatively 538 requires 8 individual loci to be sequenced, double the number of this study, for a relatively study, f

of a decline in overall infection prevalence.

539 marginal gain in DP. In addition to this, it is possible that when the mutation rate of a<br>population is too high, a high level of DP provides too much resolution, and epidemiological 540 links may be obscured (22). In this study, the higher DP highlighted the difference between 541 the diversity indices of the two timepoints in South Gondar. The *omp*A serovar type 542 suggests a loss of diversity after extra rounds of MDA, with serovar A dominating in the 543 second time point relative to the first, and the enhanced resolution provided by MLVA-544 ompA typing confirmed that the number of variants is significantly lower after extra rounds 545 ompA typing confirmed that the number of variants is significantly lower after extra rounds<br>546 of MDA. This would suggest that MDA has driven purifying selection, however whether or 546 not these STs persist in the population requires further monitoring. Surveys continue to 547 monitor trachoma in Amhara, and it is recommended that these newly collected samples 548 monitor trachoma in Amhara, are MLVA-*omp*A typed to further understand the effect of MDA on diversity and the decline 549 are MLVA-*omp*A typed to further understand the effect of MDA on diversity and the decline<br>in infection prevalence. 550 in infection prevalence.

551

552 Studies have shown that particular Ct variants have greater virulence (53,54), with<br>identification of variants usually based on WGS. The relatively simpler and less expensive 553 method of MLVA-ompA can provide sufficient resolution, enabling the study of intervention 554 effects at the population level. We did not find significant associations between high, 555 medium or low frequency STs and the clinical signs of trachoma or Ct load at village or 556 district level. It is possible that due to the restricted number of samples included, there was 557 insufficient statistical power to identify a relationship, however it is more likely that the 558 regular rounds of MDA this population underwent has limited the likelihood of a single or 559 common variant to become established and cause a significant increase in clinical signs of 560 active trachoma. MSTs support this proposition as they demonstrate an homogenous 561 active tractive track support this proposition as the $\gamma$  demonstrate an homogeneus

562 distribution of variants with  $\alpha$  lack of evidence for clustering of evidence for clus

563  $\frac{1}{\sqrt{2}}$ 

564

565 There are limitations to the MLVA-ompA typing method and our study. Firstly, mixed<br>566 infections are not able to be identified since sequencing of a mixed product cannot be 566 unequivocally interpreted, as mixed genotypes create mixed sequences (33). In addition to 567 this, in this study some samples were not able to be assigned for CT1291 and CT1299, with 568 issues associated with the repeat cytosine  $(C)$ -region. DNA polymerase slippage is a well-569 known phenomenon where tag DNA polymerase disassociates from the template and re-570 anneals at a matching base further along the strand, altering the original length of the 571 repeat region (55). This is part of the reason VNTRs have such high variation, as this happens 572 naturally during DNA replication. CT1335, which did not have any repeat Cs and had a 573 maximum number of 11 repetitions of T nucleotides, did not display this slippage. Whether 574 or not this is due to the number of repeats or cytosine itself driving polymerase slippage is 575 unknown. In other studies, however, repeat regions of 21 Cs have been recorded (56), 576 suggesting a methodological or DNA template issue. Short-read WGS struggles with repeat 577 regions, this is due to problems with alignment of short read sequences and the algorithms 578 used in next generation sequencing (NGS)/WGS pipelines (57,58). This is reflected in the 579 CT1291 and CT1299 VNTR sequences extracted from our WGS sequences from the samples 580 in this study. In addition, the maximum likelihood phylogenetic tree constructed through 581 WGS-derived sequences support this statement, wherein a significant portion of the 582 sequences were indistinguishable and clustered together, irrespective of their associated 583 STs. We found a high proportion of non-assigned bases within these two VNTR regions, as 584 well as inconsistent results with the Sanger sequencing VNTR results. One possible reason is 585 well as inconsistent results with the Sanger sequencing  $\mathcal{V}^{\mathcal{A}}$ 

586 mapping ambiguity; When aligning short reads to a reference genome, the presence of<br>VNTRs can lead to mapping ambiguity. If the number of repeats differs between the sample 587 and the reference genome, it may be challenging to accurately map the reads to the correct 588 genomic location (59). As Sanger sequencing is often used to confirm the presence of single 589 nucleotide polymorphisms found using WGS, it is assumed that the Sanger derived VNTR 590 sequences in this study are the likely the more accurate (60). 591 sequences in this study are the likely the more accurate (60).

592

593 The data from this study has shown that MLVA-ompA is a suitable technique for identifying<br>594 Ocular Ct variants on a local scale. While there were some issues surrounding long repeat 594 regions, the typeability for all three VNTRs was approximately 65%. While the typeability of 595  $ompA$  variants was above 80%, this was after a second round of nested PCR in  $\sim$ 33% of 596 ompA variants was above 80%, this was after a second round of nested PCR in ∼33% of<br>597 samples, which involved further manipulation, financial costs and increased the risk of 597 contamination. NGS techniques are associated with different issues, such as the 598 requirement for more expensive equipment, more complicated analysis pipelines and 599 computing power. It is difficult to estimate the exact cost of WGS as genome size influences 600 the number of samples that can be run in parallel, and a bioinformatician is generally 601 required to analyse the data, a substantial part of overall costs (61). The cost of performing 602 WGS by Pickering et al (2022) (31) was estimated at £250 per sample without post 603 sequencing analysis, whereas the average cost of Sanger sequencing is estimated at  $\sim$ £20 604 per sample for all four targets required for MLVA-*omp*A. Sanger sequencing also requires 605 per sample for all four targets required for MLVA-ompA. Sanger sequencing also requires<br>606 more readily available technology than WGS (since PCR amplicons can be simply posted 606 service providers). Sanger sequencing of a single product generates less data that simpler to 607 interpret with minimal training required. 608 interpret with minimal training required.

610 This dataset has provided a unique collection of samples in which to investigate the utility of<br>the MLVA-*omp*A method in a trachoma endemic region. Amhara is a region experiencing 611 the MLVA-ompA method in a trachoma endemic region. Amhara is a region experiencing<br>612 persistently high levels of trachoma (30), and is one of few programs that has been regularly 612 monitoring Ct infection with ocular swabbing and PCR. The addition of Ct monitoring to 613 trachoma programs not only allows for the tracking of Ct prevalence, but also allows for a 614 deeper understanding of variant diversity, and the efficacy of MDA, and it is recommended 615 that other programs experiencing persistent or recrudescent trachoma include ocular Ct 616 testing. The application of this typing technique provides an accessible, affordable and 617 functional tool for tracking the spread and diversity of Ct variants over time and space, 618 which can provide important information on the efficacy of MDA, aiding trachoma 619 elimination programmes in resource limited settings. 620 elimination programmes in resource limited settings.

621

#### 622 Acknowledgements

623

624

Many thanks to the late Dr Julius Schemer and Jeanie Moncada for the kind gift of<br>B/Tunis864 original DNA. The authors thank Abbott for donation of the m2000 RealTime 625 B/Tunis864 original DNA. The authors thank Abbott for donation of the m2000 RealTime<br>molecular diagnostics system and consumables.

626 molecular diagnostics system and consumables.

627

#### 628 References

![](_page_33_Picture_159.jpeg)

![](_page_34_Picture_247.jpeg)

![](_page_35_Picture_240.jpeg)

![](_page_36_Picture_237.jpeg)

![](_page_37_Picture_220.jpeg)